Planar Thinned Arrays: Optimization and Subarray Based Adaptive Processing

A new approach is presented for the optimized design of a planar thinned array; the proposed strategy works with single antenna elements or with small sets of different subarray types, properly located on a planar surface. The optimization approach is based on the maximization of an objective function accounting for side lobe level and considering a fixed number of active elements/subarrays. The proposed technique is suitable for different shapes of the desired output array, allowing the achievement of the desired directivity properties on the corresponding antenna pattern. The use of subarrays with a limited number of different shapes is relevant for industrial production, which would benefit from reduced design and manufacturing costs. The resulting modularity allows scalable antenna designs for different applications. Moreover, subarrays can be arranged in a set of subapertures, each connected to an independent receiving channel. Therefore, adaptive processing techniques could be applied to cope with and mitigate clutter echoes and external electromagnetic interferences. The performance of adaptive techniques with subapertures taken from the optimized thinned array is evaluated against assigned clutter and jamming scenarios and compared to the performance achievable considering a subarray based filled array with the same number of active elements

Identificação de fontes de resistência à ferrugem Polissora em milho e desenvolvimento de população de mapeamento.

bitstream/item/143851/1/circ-212.pd

Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients

The mPEBev is an anticancer regimen which combines a chemotherapy doublet, based on cisplatin and oral etoposide (mPE), with bevacizumab (mPEBev), a mAb targeting the vasculo-endothelial growth factor (VEGF). In previous studies, this regimen showed powerful anti-angiogenetic effects and significant antitumor activity in metastatic non-small-cell lung cancer (mNSCLC) patients. We also recorded the best benefit in patients exhibiting low-systemic inflammatory profile at baseline. On these bases, we hypothesized that mPEBev antitumor activity could be partially related to bevacizumab-associated immunological effects. For this reason, we performed an immunological monitoring in 59 out of 120 stage IIIb-IV NSCLC patients enrolled in the BEVA2007 phase II trial, who received fractioned cisplatin (30 mg/sqm days 1-3q21) and oral etoposide (50 mg, days 1-15q21) (mPE doublet) ±bevacizumab. In this group of patients, 12 received the mPE doublet alone and 47 the doublet in combination with bevacizumab (5 mg/kg on the day 3q21; mPEBev regimen). Blood cell counts, serum analysis, multiplex cytokine assay and immunocytofluorimetric analysis, performed on baseline and post-treatment on blood samples from these patients, revealed that bevacizumab addition to the doublet decreased levels of pro-angiogenic (VEGF, Angiostatin-1 and Follistatin) and inflammatory cytokines (interferon (IFN)γ, IL4 and IL17), improved in vivo and in vitro cytotoxic T-lymphocytes (CTL) response and promoted dendritic cell activation. These results suggest that the mPEBev regimen improve the micro-environmental conditions for an efficient antigen-specific CTL response, making it a feasible candidate regimen to be assessed in combination with immune-checkpoint inhibitors in NSCLC patients

Major effect qtl on chromosome 3 conferring maize resistance to Sugarcane mosaic virus.

The Sugarcane mosaic virus (SCMV), a maize pathogen epidemic worldwide, is the causal agent of common mosaic, one of the most important viral diseases in Brazil. In this study, we mapped and characterized quantitative trait loci (QTL) conferring resistance to SCMV in a maize population consisting of 127 F2:3 families from the cross between two Brazilian maize inbred lines, L18 (resistant) × L19 (susceptible). Field trials were carried out in two years to evaluate the F2:3 families according to a resistance score after artificial inoculation. QTLs were detected via composite interval mapping, using a linkage map based on 82 SSRs, 3 CAPS and 296 SNPs. The heritability ranged from 73.68 to 95.16% and SCMV resistance QTLs were consistently identified on chromosomes 1 and 3, showing minor and major effects, respectively. The major QTL on chromosome 3 explained a large proportion of the genetic variance, being 50 and 70% in year 1 and 2, respectively, while the minor QTL on chromosome 1 explained 11 and 8% in year 1 and 2, respectively. The SNP marker co-localized with the major QTL peak on chromosome 3 and its right flanking marker are positioned inside the predicted gene GRMZM2G122443 encoding a glucosidase II, and the left flanking marker inside the GRMZM2G140537 that encodes a protein tyrosine kinase. Moreover, within this QTL region there are also the GRMZM2G160902 and GRMZM2G122481 predicted genes, encoding a bZIP transcription factor and a cytochrome C oxidase, respectively. The colocalization with this major effect QTL suggests a putative involvement of these candidate genes with maize responses to SCMV resistance, but further functional studies are required for such validation. Our results provide resistance source and genomic target for marker-assisted breeding aiming the development of maize resistant cultivars to SCMV

Radiotherapy prolongs the survival of advanced non-smallcell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev)

Radiotherapy (RT), together with a direct cytolytic effect on tumor tissue, also elicits systemic immunological events, which sometimes result in the regression of distant metastases (abscopal effect). We have shown the safety and anti-tumor activity of a novel metronomic chemotherapy (mCH) regimen with dose-fractioned cisplatin, oral etoposide and bevacizumab, a mAb against the vasculo-endothelial-growthfactor (mPEBev regimen), in metastatic non-small-cell-lung cancer (mNSCLC). This regimen, designed on the results of translational studies, showed immune-modulating effects that could trigger and empower the immunological effects associated with tumor irradiation. In order to assess this, we carried out a retrospective analysis in a subset of 69 consecutive patients who received the mPEBev regimen within the BEVA2007 trial. Forty-five of these patients, also received palliative RT of one or more metastatic sites. Statistical analysis (a Log-rank test) revealed a much longer median survival in the group of patients who received RT [mCH vs mCH + RT: 12.1 +/-2.5 (95%CI 3.35-8.6) vs 22.12 +/-4.3 (95%CI 11.9-26.087) months; P=0.015] with no difference in progression-free survival. In particular, their survival correlated with the mPEBev regimen ability to induce the percentage of activated dendritic cells (DCs) (CD3-CD11b+CD15-CD83+CD80+) [Fold to baseline value (FBV) 641 vs > 1: 4+/-5.389 (95%CI,0-14.56) vs 56+/-23.05 (95%CI,10.8-101.2) months; P:0.049)] and central-memory-T-cells (CD3+CD8+CD45RA-CCR7+) [FBV 641 vs > 1: 8+/-5.96 (95%CI,0-19.68) vs 31+/-12.3 (95%CI,6.94-55.1) months; P:0.045]